Ironwood Pharmaceuticals
IRWD
124 hedge funds and large institutions have $1.32B invested in Ironwood Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 22 closing their positions.
149% more capital inflows, than outflows
Capital inflows: $180M | Capital outflows: $72M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
27% more call options, than puts
Call options by funds: $6.79M | Put options by funds: $5.34M
6.79% more ownership
Funds ownership: 77.98% → 84.76% (+6.8%)
4% less funds holding
Funds holding: 129 → 124 (-5)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$36.5M |
| 2 |
BVF Inc
San Francisco,
California
|
+$31M |
| 3 |
Millennium Management
New York
|
+$16.2M |
| 4 |
Clough Capital Partners
Boston,
Massachusetts
|
+$15.7M |
| 5 |
Janus Henderson Investors US
Denver,
Colorado
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Waddell & Reed Financial
Overland Park,
Kansas
|
-$18.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$10.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$5.4M |
| 4 |
Fortress Investment Group
New York
|
-$5.1M |
| 5 |
TCW Group
Los Angeles,
California
|
-$4.53M |
IRWD Hedge Fund Activity: Q3 2013 in Review
124 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2013, worth a combined $1.32B — up 29% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of IRWD and 19 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 51 added.
The largest buyer was Deutsche Bank, adding an estimated $36.5M. The largest seller was Waddell & Reed Financial, cutting an estimated $18.7M.
- 124 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2013, down from 129 in Q2 2013.
- Funds reported $1.32B of Ironwood Pharmaceuticals stock for Q3 2013, up 29% quarter-over-quarter.
- 19 funds opened new Ironwood Pharmaceuticals positions in Q3 2013 and 22 closed out, a net change of -3 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2013 was Deutsche Bank, an estimated $36.5M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2013 was Waddell & Reed Financial, an estimated $18.7M sold.
Based on aggregated 13F filings for Q3 2013.